Kiniksa Q3 ARCALYST revenue $286M (+58% YoY), FY26 outlook up to $1.045–1.050B; penetration, profit up

 

• ARCALYST penetration of 14,000 multi-recurrence patients reached 23%, up from 18% FY25.
• Quarterly ARCALYST sales grew $42.5M sequentially, driven by prescriber growth and DTC.
• Collaboration profit $211.6M, +67% YoY, outpacing revenue growth via disciplined commercial investment.
• Operating income $54.2M, net income $47.3M; cash rose $43M to $568.8M.
• 2026 guidance: ARCALYST revenue $1.045–$1.050B; R&D $160–$170M; SG&A $270–$280M.
• KPL-387 Phase III pivotal trial enrolling globally; top-line data expected 2H27, launch 2028–2029.
• KPL-1161, quarterly IL-1 inhibitor, entering Phase I by year-end, enabling broader chronic indications.
• AI-enabled Heart's Home DTC drove 12x web traffic, 8x engagement; 55% plan HCP discussions.
• Main risks: ARCALYST concentration, long KPL-387 timeline, increasing R&D and SG&A commitments.
• Main concern: heavy reliance on ARCALYST while key diversification asset KPL-387 will not read out until 2H27.
• Strong quarter, driven by accelerating ARCALYST penetration, rising profitability, and raised full-year revenue guidance.

https://finviz.com/stock?t=KNSA&p=d